

Gonzalo Merino, Ph.D.
Associate
Direct: 212-541-1258
GGMERINO@BRYANCAVE.COM

Mail Stop Amendment Commissioner for Patents P.O. Box. 1450 Alexandria, VA 22313-1450 Bryan Cave LLP

1290 Avenue of the Americas New York, NY 10104-3300 Tel (212) 541-2000 Fax (212) 541-4630

www.bryancave.com

Re:

U.S. Patent Application Serial No.: 10/053,192

Filed: January 15, 2002

For:

β, β-CAROTENE 15,15'-MONOOXYGENASES, NUCLEIC ACID

SEQUENCES CODING THEREFOR AND THEIR USE

Docket No.: 20347 US1 (C038435/0128985)

Sir:

Enclosed is a completed Terminal Disclaimer. Pursuant to Rule 1.20(d), enclosed is a check in the amount of \$110.00 to cover the fee for the filing of this Terminal Disclaimer. Please charge any required fees not otherwise paid by check to Deposit Account No. 02-4467. A duplicate copy of this letter is enclosed.

Chicago

Hong Kong

Irvine

Jefferson City

Kansas City

Kuwait

Los Angeles

New York

Phoenix

Riyadh

Shanghai

St. Louis

United Arab Emirates (Dubai)

Washington, DC

And Bryan Cave, A Multinational Partnership,

London

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Box Amendment, Commissioner for Patents, P.O. Box. 1450 Alexandria, VA 22313-1450, on August 3, 2004.

Gonzalo Merino, Ph.D., Reg. No. 51,192

Gonzalo Merino, Ph.D.

Reg. No. 51,192

Respectfully submitted,

BRYAN CAVE LLP

1290 Avenue of the Americas New York, NY 10104-3300

Phone: (212) 541-2000

Fax: (212) 541-4630

PTO/SB/25 (08-03) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING REJECTION OVER A PENDING SECOND APPLICATION

Docket Number (Optional)

20347 US1 (C038435/0128985)

Heinrich BACHMANN et al. In re Application of: Application No.: 10/053,192 Filed: January 15, 2002 For: Beta, beta-CAROTENE 15,15'-MONOOXYGENASES, NUCLEIC ACID SEQUENCES CODING THEREFOR AND THEIR USE

08/06/200 01 FC:181

The owner*, DSM Nutritional Products, Inc., of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 and 173 as shortened by any terminal disclaimer filed prior to the grant of any patent granted on pending second Application Number ___ filed on February 15, 2000 , of any patent on the pending second application. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the second application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of any by all ull

event that any such granted patent: expires for failure to pay a rate of competent jurisdiction, is statutorily disclaimed in which claims canceled by a reexamination certificate, is reissued, or is statutory term as shortened by any terminal disclaimer filed prior	maintenance fee, is held unenforceable, nole or terminally disclaimed under 37 C s in any manner terminated prior to the s	is found invalid by CFR 1.321, has all
Check either box 1 or 2 below, if appropriate.		
1. For submissions on behalf of an organization (e.g., coetc.), the undersigned is empowered to act on behalf	orporation, partnership, university, governof the organization.	nment agency,
I hereby declare that all statements made herein of my information and belief are believed to be true; and further that th false statements and the like so made are punishable by fine or the United States Code and that such willful false statements missued thereon.	nese statements were made with the kno r imprisonment, or both, under Section 1	owledge that willful 1001 of Title 18 of
2. The undersigned is an attorney or agent of record.	Signature	8/3/04 Date
DEMMANU1 00000015 10053192	Gonzalo Merino, Ph.D., Reg. No.	51 102
110.00 OP	Typed or printed name	
	Phone: (212) 541-2000 Fax: (212) 541-4630	
	Telephone Number	
Terminal disclaimer fee under 37 CFR 1.20(d) is included.		
MADNING LC CC CC		

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this statement. See MPEP § 324.

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.